Cargando…
Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study
INTRODUCTION: The aim of this study was to examine ranibizumab treatment patterns in “real-world” practice and clinical settings, as well as to assess quality of life outcomes over a 24-month period. MATERIALS AND METHODS: This was a prospective, observational, multicenter, open-label study of 0.5 m...
Autores principales: | Rakic, Jean-Marie, Leys, Anita, Brié, Heidi, Denhaerynck, Kris, Pacheco, Christy, Vancayzeele, Stefaan, Hermans, Christine, MacDonald, Karen, Abraham, Ivo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3788820/ https://www.ncbi.nlm.nih.gov/pubmed/24092964 http://dx.doi.org/10.2147/OPTH.S49385 |
Ejemplares similares
-
Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUS(TM) Study
por: Leys, Anita M, et al.
Publicado: (2020) -
Real-World Outcomes in Patients with Diabetic Macular Edema Treated Long Term with Ranibizumab (VISION Study)
por: Van Aken, Elisabeth, et al.
Publicado: (2020) -
Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006) -
Clinical, Quality of Life, Patient Adherence, and Safety Outcomes of Short-Course (12 Weeks) Treatment with Cyclosporine in Patients with Severe Psoriasis (the Practice Study)
por: Swimberghe, Sandra, et al.
Publicado: (2013) -
The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited
por: Brown, Gary C., et al.
Publicado: (2017)